|
N/A
|
ACN12001-001
|
$270
|
-, -
|
NASA/JPL JET PROPULSION LABORA
|
|
(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
|
1R01CA227479-01
|
$351,726
|
SIMONE, NICOLE
|
THOMAS JEFFERSON UNIVERSITY
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
5R01CA216248-02
|
$607,904
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
1R01CA227473-01
|
$580,767
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy
|
5R01CA208526-03
|
$472,047
|
CUCINOTTA, FRANCIS
|
UNIVERSITY OF NEVADA LAS VEGAS
|
|
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics
|
5R01CA215802-02
|
$511,546
|
SPARREBOOM, ALEXANDER
|
OHIO STATE UNIVERSITY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity
|
1R01CA227493-01
|
$427,990
|
MARPLES, BRIAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
(PQ 5) Roles of mitochondrial heterogeneity in cell survival and oncogenesis
|
5R21CA216304-02
|
$195,750
|
NEWMEYER, DONALD
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
5R01CA205965-02
|
$640,839
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
5R21CA215985-02
|
$165,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-03
|
$630,724
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
5R21CA206013-02
|
$169,500
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
5R01CA205258-03
|
$464,261
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-03
|
$415,599
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-03
|
$703,249
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-03
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral niche
|
5R01CA216054-02
|
$324,411
|
HAYDEN GEPHART, MELANIE
|
STANFORD UNIVERSITY
|
|
(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated Cancer
|
5R01CA206483-02
|
$570,958
|
EMU, BRINDA
|
YALE UNIVERSITY
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
|
1R21CA227232-01
|
$208,746
|
TURNBAUGH, PETER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
|
1R01CA219871-01A1
|
$451,326
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
|
1R21CA227528-01
|
$176,175
|
WEICHSELBAUM, RALPH
|
UNIVERSITY OF CHICAGO
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions
|
1R01CA227237-01
|
$686,519
|
GUSEV, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-03
|
$706,386
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-03
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
5R01CA206477-03
|
$791,933
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer
|
5R01CA206465-03
|
$512,833
|
JUSTICE, AMY
|
YALE UNIVERSITY
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
5R01CA194461-04
|
$334,291
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
(PQ5) Consequences of imbalanced mitophagy and mitochondrial biogenesis in cancer
|
5R01CA216242-02
|
$319,238
|
MACLEOD, KAY
|
UNIVERSITY OF CHICAGO
|
|
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa
|
5R01CA217138-02
|
$723,817
|
WARREN, EDUS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Informing anal neoplasia differences/similarities in HIV-serodiscordant individuals
|
5R21CA216830-02
|
$192,500
|
SHIRAMIZU, BRUCE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-03
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
|
5R01CA206012-03
|
$403,884
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting
|
1R01CA216254-01A1
|
$413,916
|
HAJNOCZKY, GYORGY
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
5R01CA206005-03
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-03
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ6) Roles of circadian rhythms in tumor development
|
1R21CA227379-01
|
$208,800
|
HONG, CHRISTIAN
|
UNIVERSITY OF CINCINNATI
|
|
(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
|
1R21CA227375-01
|
$224,199
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-03
|
$522,325
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-03
|
$384,612
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
5R01CA216273-02
|
$740,321
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
5R01CA206028-03
|
$342,846
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-03
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|